Literature DB >> 27459117

Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells.

Yuri Cho1, Eun Ju Cho2, Jeong-Hoon Lee2, Su Jong Yu2, Yoon Jun Kim2, Chung Yong Kim2, Jung-Hwan Yoon3.   

Abstract

Hepatocellular carcinoma (HCC) is a fast growing tumor associated with a high tendency for vascular invasion and distant metastasis. Recently, we reported that fucoidan displays inhibitory effect on proliferation and invasion of HCC cells. In this study, we investigated the anti-metastatic effect of fucoidan on HCC cells and the key signal that modulates metastasis. The anti-metastatic effect of fucoidan was evaluated in vitro using an invasion assay with human HCC cells (Huh-7, SNU-761, and SNU-3085) under both normoxic (20% O2 and 5% CO2, at 37°C) and hypoxic (1% O2, 5% CO2, and 94% N2, at 37°C) conditions. Complementary DNA (cDNA) microarray analysis was performed to find the molecule which is significantly suppressed by fucoidan. In vivo study using a distant metastasis model by injecting SNU-761 cells into spleen via portal vein was performed to confirm the inhibitory effect by small interfering RNA (siRNA) transfection. Immunoblot analyses were used to investigate the signaling pathway. Fucoidan significantly suppressed the invasion of human HCC cells (Huh-7, SNU-761, and SNU-3085). Using cDNA microarray analysis, we found the molecule, ID-1, which was significantly suppressed by fucoidan treatment. Downregulation of ID-1 by siRNA significantly decreased invasion of HCC cells, both in vitro and in vivo (both P<0.05) in a NDRG-1/CAP43-dependent manner. In immunoblot assay, downregulation of ID-1 by siRNA decreased the expressions of epithelial-mesenchymal transition markers including CK19, vimentin, MMP2, and fibronectin. Immunofluorescence study also revealed that actin rearrangement was inhibited when ID-1 was down-regulated in HCC cells. Interestingly, in SNU-761 cells, the ID-1 expressions under hypoxic conditions were lower as compared to those under normoxic conditions. Under hypoxic conditions, HIF-1α up-regulated NDRG-1/CAP43, while HIF-2α down-regulated ID-1, which might be a compensatory phenomenon against hypoxia-induced HCC invasion. In conclusion, NDRG-1/CAP43-dependent down-regulation of ID-1 suppressed HCC invasion both in vitro and in vivo, which was modulated by fucoidan treatment. Moreover, the compensatory down-regulation of ID-1 against hypoxia-induced HCC invasion was observed. ID-1 is a novel therapeutic target for the treatment of metastatic HCC.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Fucoidan; Hepatocellular carcinoma; Hypoxia; ID-1; Metastasis; NDRG/CAP43

Mesh:

Substances:

Year:  2016        PMID: 27459117     DOI: 10.1016/j.biopha.2016.07.027

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  12 in total

1.  Identification of a Pro-Angiogenic Potential and Cellular Uptake Mechanism of a LMW Highly Sulfated Fraction of Fucoidan from Ascophyllum nodosum.

Authors:  Nicolas Marinval; Pierre Saboural; Oualid Haddad; Murielle Maire; Kevin Bassand; Frederic Geinguenaud; Nadia Djaker; Khadija Ben Akrout; Marc Lamy de la Chapelle; Romain Robert; Olivier Oudar; Erwan Guyot; Christelle Laguillier-Morizot; Angela Sutton; Cedric Chauvierre; Frederic Chaubet; Nathalie Charnaux; Hanna Hlawaty
Journal:  Mar Drugs       Date:  2016-10-17       Impact factor: 5.118

2.  Id-1 promotes migration and invasion of non-small cell lung cancer cells through activating NF-κB signaling pathway.

Authors:  Jie Li; Yingjie Li; Bin Wang; Yongfu Ma; Ping Chen
Journal:  J Biomed Sci       Date:  2017-12-12       Impact factor: 8.410

Review 3.  Clinical applications of fucoidan in translational medicine for adjuvant cancer therapy.

Authors:  Hsien-Yeh Hsu; Pai-An Hwang
Journal:  Clin Transl Med       Date:  2019-05-01

4.  Fucoidan Derived from Fucus vesiculosus Inhibits the Development of Human Ovarian Cancer via the Disturbance of Calcium Homeostasis, Endoplasmic Reticulum Stress, and Angiogenesis.

Authors:  Hyocheol Bae; Jin-Young Lee; Changwon Yang; Gwonhwa Song; Whasun Lim
Journal:  Mar Drugs       Date:  2020-01-09       Impact factor: 5.118

Review 5.  The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles.

Authors:  Jun-O Jin; Pallavi Singh Chauhan; Ananta Prasad Arukha; Vishal Chavda; Anuj Dubey; Dhananjay Yadav
Journal:  Mar Drugs       Date:  2021-05-10       Impact factor: 5.118

Review 6.  Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy.

Authors:  Zhengxiao Zhao; Zhiyuan Bo; Weiyi Gong; Yong Guo
Journal:  Int J Med Sci       Date:  2020-04-06       Impact factor: 3.738

7.  Fucoidan Inhibition of Osteosarcoma Cells Is Species and Molecular Weight Dependent.

Authors:  Dhanak Gupta; Melissa Silva; Karolina Radziun; Diana C Martinez; Christopher J Hill; Julie Marshall; Vanessa Hearnden; Miguel A Puertas-Mejia; Gwendolen C Reilly
Journal:  Mar Drugs       Date:  2020-02-08       Impact factor: 5.118

Review 8.  The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations.

Authors:  Yuan Lin; Xingsi Qi; Hengjian Liu; Kuijin Xue; Shan Xu; Zibin Tian
Journal:  Cancer Cell Int       Date:  2020-05-07       Impact factor: 5.722

9.  Fucoidan Induces Apoptosis and Inhibits Proliferation of Hepatocellular Carcinoma via the p38 MAPK/ERK and PI3K/Akt Signal Pathways.

Authors:  Yifei Duan; Jingjing Li; Xue Jing; Xueli Ding; Yanan Yu; Qingxi Zhao
Journal:  Cancer Manag Res       Date:  2020-03-09       Impact factor: 3.989

10.  CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.

Authors:  Young Chang; Yun Bin Lee; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  BMC Cancer       Date:  2020-10-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.